The demand for Indian generic drugs has shot up in China amid the massive COVID surge in the country, with Chinese experts cautioning that fake versions of these drugs are flooding the market. China’s National Health Security Administration said on Sunday that Pfizer’s Paxlovid oral medication, which is used to treat Covid-19, could not be included in the “register of drugs in the basic medical insurance”, because the company’s quotation was too high, media reports here said. Due to the massive short supply of Paxlovid, demand for Indian generic versions has gone up through Chinese e-commerce platforms. “On the Chinese…